Ifetroban is a potent and selective thromboxane receptor antagonist, and has been studied in other diseases. This drug is aimed at cardiac function and has shown to be effective in other cardiac indications. The current study aims to address the unmet medical need to treat Duchenne cardiomyopathy using a new therapeutic strategy for patients with Duchenne muscular dystrophy.
A Phase 2 randomized, double-blind, placebo-controlled, multiple dose study to determine the safety, pharmacokinetics and efficacy of two doses of oral ifetroban in subjects with Duchenne muscular dystrophy is actively recruiting.
Ifetroban has been studied in 26 clinical trials and dosed in over 1,300 people including healthy volunteers. There are additional active clinical trials evaluating ifetroban in other rare diseases.
This program is sponsored by Cumberland Pharmaceuticals.
|Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy|
Cumberland Pharmaceuticals Presents at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library
Cumberland Pharmaceuticals Presents at the PPMD 2020 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library
Larry Markham, PhD Presents at the PPMD 2019 Annual Conference